Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study
Authors:
- 1 November 2021
- Vol. 39 (46) , 6787-6795
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 15 references indexed in Scilit:
- Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15The Lancet Global Health, 2018
- Burden of bacterial meningitis in India: Preliminary data from a hospital based sentinel surveillance networkPLOS ONE, 2018
- Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trialVaccine, 2017
- Burden of Severe Pneumonia, Pneumococcal Pneumonia and Pneumonia Deaths in Indian States: Modelling Based EstimatesPLOS ONE, 2015
- Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years — India, 2014 and updates on immunizationIndian Pediatrics, 2014
- Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Vaccines in IndiaThe Pediatric Infectious Disease Journal, 2013
- Conjugate pneumococcal vaccines: Need and choice in IndiaIndian Journal of Community Medicine, 2013
- Preservative of choice for Prev(e)nar 13™ in a multi-dose formulationVaccine, 2011
- Single versus multi-dose vaccine vials: An economic computational modelVaccine, 2010
- Antimicrobial preservative use in parenteral products: Past and presentJournal of Pharmaceutical Sciences, 2007